SNTI

Senti Biosciences Holdings, Inc. - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

Senti Biosciences, Inc. (SNTI) is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. The company is focused on oncology indications, with its lead product candidate, SENTI-202, currently in Phase 1 clinical trials for relapsed/refractory hematologic malignancies. This report covers the quarterly period ended September 30, 2025. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.

Key Financial Metrics

Note: The company has no product revenue. Cash flow is driven by operating losses, financing activities, and grants.

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss for Q3 2025 decreased to $18.1 million from $28.9 million in Q3 2024. This improvement was primarily driven by the absence of significant fair value losses on the GeneFab Note Receivable (which was waived in late 2024) and a reversal of sublease income due to collectibility issues.
• Operating Expenses: Total operating expenses increased by $1.7 million in Q3 2025 compared to Q3 2024, driven by higher Research and Development (R&D) costs ($10.5M vs $8.7M) due to increased external services and personnel costs.
• Sublease Income Reversal: In Q3 2025, the company recorded a $3.3 million reversal of previously recognized sublease income from GeneFab due to a determination that collectibility was no longer probable. This resulted in a net sublease expense of $1.6 million for the quarter, compared to income of $1.7 million in the prior year.
• Capital Structure: In March 2025, the company converted all outstanding Series A redeemable convertible preferred stock (21,157 shares) into 21,157,000 shares of common stock. As of September 30, 2025, there is no preferred stock outstanding.
• Cash Position: Cash and cash equivalents declined significantly from $48.3 million at year-end 2024 to $12.2 million at September 30, 2025, reflecting a net cash burn of approximately $36 million over the nine-month period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the filing date. The company's cash balance of $12.2 million is deemed insufficient to fund operations for the next 12 months without additional financing.
• GeneFab Default: GeneFab, a related party and key manufacturing partner, is in default on sublease payments. As of September 30, 2025, GeneFab owed $4.7 million in past-due rent. Consequently, the company received a notice of default from its landlord for the Alameda facility for nonpayment of approximately $0.4 million. The company is in discussions to cure this default.
• Clinical Updates:
  • SENTI-202: The company announced the Recommended Phase 2 Dose (RP2D) in August 2025. Enrollment in the expansion cohort is ongoing, with topline data expected before the end of 2025.
  • SN301A: The partner, Celest Therapeutics, stopped dosing in the SN301A clinical trial in China due to observed dose-limiting toxicities.
• Financing Activities: The company terminated its Common Stock Purchase Agreement with Chardan in March 2025 and entered into a new At-The-Market (ATM) agreement with Leerink Partners for up to $17.5 million. Net proceeds from the ATM in the first nine months of 2025 were less than $0.1 million.
• Internal Controls: The company previously identified a material weakness in internal controls over financial reporting related to insufficient resources in the finance function. Management believes this weakness has been remediated as of June 30, 2025.

Key Facts for Investor Verification

• Liquidity Runway: Verify the company's ability to raise capital immediately, given the explicit "substantial doubt" regarding going concern status and a cash balance of only $12.2 million.
• GeneFab Resolution: Monitor the status of the $4.7 million receivable from GeneFab and the resolution of the Alameda facility lease default, as failure to resolve these could disrupt manufacturing and operations.
• SENTI-202 Data: Await the topline data from the SENTI-202 Phase 1 expansion cohort expected before the end of 2025, which is critical for future valuation and funding.
• SN301A Impact: Assess the strategic impact of the halted SN301A trial in China on the company's pipeline diversification and partnership strategy.
• Dilution Risk: Note the existence of 31.7 million warrants outstanding (exercise price $2.30) and the potential for significant dilution if the company pursues equity financing to address its liquidity needs.